Companion Animal Health Program
We believe our NITRICIL™ technology has the potential to address antimicrobial indications. Our new chemical entity, NVN4100, has the potential to treat resistant strains and minimize risk of developing resistance to antibiotics. We have engaged third-party animal health experts to work with us to determine the technical feasibility and the market potential and are currently looking at a number of therapeutic indications. We have utilized internal resources to undertake the initial formulation development to assess viability and upon that positive proof-of-concept, we would engage collaborators and/or strategic partners.
Initial formulation development to assess viability in progress
Engaged third-party animal health experts to determine technical feasibility and market potential
Upon positive proof of concept, engage with potential collaborators and strategic partners